Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Back to Search
Print
Bookmark Trial

NCT00863798

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmingham, Alabama, 35216, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening).

- Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of >= 20.

- Clinical Global Impressions Scale-Severity (CGI-S) score of >= 4.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Clinical instability (25% or greater increase/decrease in HAM-D 17 total score from
screening to baseline).


- Significant risk of suicide as assessed by clinician judgment, HAM-D 17 and Columbia
Suicide-Severity Rating Scale scores Other eligibility criteria also apply.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Major Depressive DisorderA Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
NCT00644982
  1. Cairns, Queensland
  2. Everton Park, Queensland
  3. North Cairns, Queensland
  4. Box Hill, Victoria
  5. Heidelberg, Victoria
  6. West Heidelberg, Victoria
  7. West Perth, Western Australia
  8. Adana,
  9. Ankara,
  10. Diyarbakir,
  11. Istanbul,
  12. Izmir,
  13. Izmit,
  14. Malatya,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
NCT00384033
  1. Beverly Hills, California
  2. Burbank, California
  3. Encino, California
  4. Los Alamitos, California
  5. Newport Beach, California
  6. Northridge, California
  7. Orange, California
  8. Pasadena, California
  9. Upland, California
  10. South Miami, Florida
  11. St. Petersburg, Florida
  12. Edwardsville, Illinois
  13. Farmington Hills, Michigan
  14. Flint, Michigan
  15. Okemos, Michigan
  16. Clementon, New Jersey
  17. Dayton, Ohio
  18. Portland, Oregon
  19. Philadelphia, Pennsylvania
  20. Salt Lake City, Utah
  21. Seattle, Washington
  22. Brown Deer, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderRelapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
NCT00887224
  1. Beverly Hills, California
  2. Encino, California
  3. Los Alamitos, California
  4. Orange, California
  5. Upland, California
  6. Aurora, Colorado
  7. Jacksonville, Florida
  8. South Miami, Florida
  9. St. Petersburg, Florida
  10. St. Petersburg, Florida
  11. Atlanta, Georgia
  12. Smyrna, Georgia
  13. Hoffman Estates, Illinois
  14. Rockville, Maryland
  15. New York, New York
  16. New York, New York
  17. Rochester, New York
  18. Dayton, Ohio
  19. Portland, Oregon
  20. San Antonio, Texas
  21. Seattle, Washington
  22. Edmonton, Alberta
  23. Medicine Hat, Alberta
  24. Kelowna, British Columbia
  25. Vancouver, British Columbia
  26. Bathurst, New Brunswick
  27. Burlington, Ontario
  28. Ottawa, Ontario
  29. Toronto, Ontario
  30. Gatineau, Quebec
  31. Pointe-Claire, Quebec
  32. Sherbrooke, Quebec
  33. Santiago,
  34. Santiago,
  35. Santiago,
  36. Medellin, Antioquia
  37. Barranquilla, Atlantico
  38. Bogota, Cundinamarca
  39. Bucamaranga, Santander
  40. Rijeka,
  41. Zagreb,
  42. Tallinn,
  43. Tallinn,
  44. Tartu,
  45. Voru,
  46. Vöru,
  47. Espoo,
  48. Helsinki,
  49. Joensuu,
  50. Kuopio,
  51. Seinajoki,
  52. Tampere,
  53. Turku,
  54. Caen,
  55. Dole,
  56. Douai,
  57. Orvault,
  58. Rennes,
  59. Liepaja,
  60. Sigulda,
  61. Sigulda,
  62. Strenci,
  63. Kaunas,
  64. Kaunas,
  65. Vilius,
  66. Vilnius,
  67. Vilnius,
  68. Vilnius,
  69. Skorzewo, Poznan
  70. Szczecin,
  71. Torun,
  72. Tuszyn,
  73. Wroclaw,
  74. Zuromin,
  75. Craiova, Dolj
  76. Brasov,
  77. Bucharest,
  78. Bucuresti,
  79. Bucuresti,
  80. Cluj Napoca,
  81. Bojnice,
  82. Bratislava,
  83. Liptovsky Mikulas,
  84. Michalovce,
  85. Rimavska Sobota,
  86. Trencin,
  87. Cape Town, Western Cape
  88. Durban,
  89. Paarl,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
NCT01056289
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder
Brief Summary The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Major Depressive Disorder
Intervention  ICMJE
  • Drug: Desvenlafaxine Succinate Sustained-Release 10mg
    10 mg tablet, once daily dosing for 8 weeks
  • Drug: Desvenlafaxine Succinate Sustained-Release 50 mg
    50 mg tablet, once daily dosing for 8 weeks
  • Drug: placebo
    Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study Arms  ICMJE
  • Experimental: Desvenlafaxine succinate sustained release 10 mg
    Intervention: Drug: Desvenlafaxine Succinate Sustained-Release 10mg
  • Experimental: Desvenlafaxine succinate sustained release 50 mg
    Intervention: Drug: Desvenlafaxine Succinate Sustained-Release 50 mg
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 27, 2010)		682
Original Estimated Enrollment  ICMJE
 (submitted: March 17, 2009)		678
Actual Study Completion Date  ICMJE March 2010
Actual Primary Completion Date March 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening).
  • Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of >= 20.
  • Clinical Global Impressions Scale-Severity (CGI-S) score of >= 4.

Exclusion Criteria:

  • Clinical instability (25% or greater increase/decrease in HAM-D 17 total score from screening to baseline).
  • Significant risk of suicide as assessed by clinician judgment, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00863798
Other Study ID Numbers  ICMJE 3151A1-3362
B2061005
3151A1-3362-US
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP